Liver X receptors as regulators of macrophage inflammatory and metabolic pathways

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1812, Issue 8, 2011, Pages 982-994

  A González, Noelia ^b   Castrillo, Antonio ^a,b  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

Author keywords

Autoimmunity; Cholesterol; Innate immunity; Liver X receptors; Macrophage; Phagocytosis

Indexed keywords

22 HYDROXYCHOLESTEROL; 24 HYDROXYCHOLESTEROL; 25 EPOXYCHOLESTEROL; 26 HYDROXYCHOLESTEROL; 3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; ABC TRANSPORTER A1; APOLIPOPROTEIN C; APOLIPOPROTEIN C IV; APOLIPOPROTEIN C1; APOLIPOPROTEIN C2; APOLIPOPROTEIN E; ATI 829; BILE ACID; CHOLESTEROL; CHOLESTEROL 7ALPHA MONOOXYGENASE; DMHCA; DNA; GAMMA INTERFERON; GLUCOSE; INTERLEUKIN 10; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; OXYSTEROL; PROTEIN BCL XL; SITOSTEROL; STEROL; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; WAY 252623;

APOPTOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; BACILLUS ANTHRACIS; BACTERIAL INFECTION; BILE; BINDING AFFINITY; CARDIOVASCULAR RISK; CELL PROLIFERATION; CELLULAR IMMUNITY; CHLAMYDOPHILA PNEUMONIAE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CHROMOSOME; CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG TARGETING; ESCHERICHIA COLI; GENE EXPRESSION; GENETIC TRANSCRIPTION; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION SENSITIVITY; INSULIN RESISTANCE; LIPID METABOLISM; LIPOGENESIS; LISTERIA MONOCYTOGENES; MACROPHAGE; METABOLIC DISORDER; METABOLIC REGULATION; METABOLISM; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; RECEPTOR BINDING; REVIEW; SALMONELLA TYPHIMURIUM; T LYMPHOCYTE;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; APOPTOSIS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INFLAMMATION MEDIATORS; MACROPHAGES; ORPHAN NUCLEAR RECEPTORS; TRANSCRIPTION FACTORS;

EID: 79958763372     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2010.12.015     Document Type: Review

References (199)

1. Chambon P. How I became one of the fathers of a superfamily. Nat. Med. 2004, 10:1027-1031.
2. Evans R. A transcriptional basis for physiology. Nat. Med. 2004, 10:1022-1026.
3. Jensen E.V. From chemical warfare to breast cancer management. Nat. Med. 2004, 10:1018-1021.
4. Chawla A., Repa J.J., Evans R.M., Mangelsdorf D.J. Nuclear receptors and lipid physiology: opening the X-files. Science 2001, 294:1866-1870.
5. Kliewer S.A., Lehmann J.M., Willson T.M. Orphan nuclear receptors: shifting endocrinology into reverse. Science 1999, 284:757-760.
6. Willson T.M., Moore J.T. Genomics versus orphan nuclear receptors-a half-time report. Mol. Endocrinol. 2002, 16:1135-1144.
7. Repa J.J., Mangelsdorf D.J. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu. Rev. Cell Dev. Biol. 2000, 16:459-481.
8. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K., Blumberg B., Kastner P., Mark M., Chambon P., et al. The nuclear receptor superfamily: the second decade. Cell 1995, 83:835-839.
9. Evans R.M., Barish G.D., Wang Y.X. PPARs and the complex journey to obesity. Nat. Med. 2004, 10:355-361.
10. Glass C.K., Saijo K. Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat. Rev. Immunol. 2010, 10:365-376.
11. Weinberger C., Hollenberg S.M., Ong E.S., Harmon J.M., Brower S.T., Cidlowski J., Thompson E.B., Rosenfeld M.G., Evans R.M. Identification of human glucocorticoid receptor complementary DNA clones by epitope selection. Science 1985, 228:740-742.
12. Govindan M.V., Devic M., Green S., Gronemeyer H., Chambon P. Cloning of the human glucocorticoid receptor cDNA. Nucleic Acids Res. 1985, 13:8293-8304.
13. Willson T.M., Jones S.A., Moore J.T., Kliewer S.A. Chemical genomics: functional analysis of orphan nuclear receptors in the regulation of bile acid metabolism. Med. Res. Rev. 2001, 21:513-522.
14. Mangelsdorf D.J., Evans R.M. The RXR heterodimers and orphan receptors. Cell 1995, 83:841-850.
15. Blumberg B., Evans R.M. Orphan nuclear receptors-new ligands and new possibilities. Genes Dev. 1998, 12:3149-3155.
16. Rosenfeld M.G., Lunyak V.V., Glass C.K. Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev. 2006, 20:1405-1428.
17. Perissi V., Jepsen K., Glass C.K., Rosenfeld M.G. Deconstructing repression: evolving models of co-repressor action. Nat. Rev. Genet. 2010, 11:109-123.
18. O'Malley B.W., Qin J., Lanz R.B. Cracking the coregulator codes. Curr. Opin. Cell Biol. 2008, 20:310-315.
19. Beaven S.W., Tontonoz P. Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia. Annu. Rev. Med. 2006, 57:313-329.
20. Bensinger S.J., Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008, 454:470-477.
21. Huang W., Glass C.K. Nuclear receptors and inflammation control: molecular mechanisms and pathophysiological relevance. Arterioscler. Thromb. Vasc. Biol. 2010, 30:1542-1549.
22. Olefsky J.M., Glass C.K. Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol. 2010, 72:219-246.
23. Apfel R., Benbrook D., Lernhardt E., Ortiz M.A., Salbert G., Pfahl M. A novel orphan receptor specific for a subset of thyroid hormone-responsive elements and its interaction with the retinoid/thyroid hormone receptor subfamily. Mol. Cell. Biol. 1994, 14:7025-7035.
24. Willy P.J., Umesono K., Ong E.S., Evans R.M., Heyman R.A., Mangelsdorf D.J. LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev. 1995, 9:1033-1045.
25. Song C., Kokontis J.M., Hiipakka R.A., Liao S. Ubiquitous receptor: a receptor that modulates gene activation by retinoic acid and thyroid hormone receptors. Proc. Natl Acad. Sci. USA 1994, 91:10809-10813.
26. Shinar D.M., Endo N., Rutledge S.J., Vogel R., Rodan G.A., Schmidt A. NER, a new member of the gene family encoding the human steroid hormone nuclear receptor. Gene 1994, 147:273-276.
27. Teboul M., Enmark E., Li Q., Wikstrom A.C., Pelto-Huikko M., Gustafsson J.A. OR-1, a member of the nuclear receptor superfamily that interacts with the 9-cis-retinoic acid receptor. Proc. Natl Acad. Sci. USA 1995, 92:2096-2100.
28. Seol W., Choi H.S., Moore D.D. Isolation of proteins that interact specifically with the retinoid X receptor: two novel orphan receptors. Mol. Endocrinol. 1995, 9:72-85.
29. Willy P.J., Mangelsdorf D.J. Unique requirements for retinoid-dependent transcriptional activation by the orphan receptor LXR. Genes Dev. 1997, 11:289-298.
30. Janowski B.A., Willy P.J., Devi T.R., Falck J.R., Mangelsdorf D.J. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 1996, 383:728-731.
31. Forman B.M., Ruan B., Chen J., Schroepfer G.J., Evans R.M. The orphan nuclear receptor LXRalpha is positively and negatively regulated by distinct products of mevalonate metabolism. Proc. Natl Acad. Sci. USA 1997, 94:10588-10593.
32. Lehmann J.M., Kliewer S.A., Moore L.B., Smith-Oliver T.A., Oliver B.B., Su J.L., Sundseth S.S., Winegar D.A., Blanchard D.E., Spencer T.A., Willson T.M. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J. Biol. Chem. 1997, 272:3137-3140.
33. Mitro N., Mak P.A., Vargas L., Godio C., Hampton E., Molteni V., Kreusch A., Saez E. The nuclear receptor LXR is a glucose sensor. Nature 2007, 445:219-223.
34. Plat J., Nichols J.A., Mensink R.P. Plant sterols and stanols: effects on mixed micellar composition and LXR (target gene) activation. J. Lipid Res. 2005, 46:2468-2476.
35. Schultz J.R., Tu H., Luk A., Repa J.J., Medina J.C., Li L., Schwendner S., Wang S., Thoolen M., Mangelsdorf D.J., Lustig K.D., Shan B. Role of LXRs in control of lipogenesis. Genes Dev. 2000, 14:2831-2838.
36. Collins J.L., Fivush A.M., Watson M.A., Galardi C.M., Lewis M., Moore L., Parks D., Wilson J., Tippin T.K., Binz J.G., Plunket K.D., Morgan D.G., Beaudet E.J., Whitney K.D., Kliewer S.A., Willson T.M. Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines. J. Med. Chem. 2002, 45:1963-1966.
37. Tontonoz P., Mangelsdorf D.J. Liver x receptor signaling pathways in cardiovascular disease. Mol. Endocrinol. 2003, 17:985-993.
38. Chawla A., Boisvert W.A., Lee C.H., Laffitte B.A., Barak Y., Joseph S.B., Liao D., Nagy L., Edwards P.A., Curtiss L.K., Evans R.M., Tontonoz P. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell 2001, 7:161-171.
39. Joseph S.B., Bradley M.N., Castrillo A., Bruhn K.W., Mak P.A., Pei L., Hogenesch J., O'Connell Test M. article sample title placed here. Cell 2004, 119:299-309.
40. Whitney K.D., Watson M.A., Goodwin B., Galardi C.M., Maglich J.M., Wilson J.G., Willson T.M., Collins J.L., Kliewer S.A. Liver X receptor (LXR) regulation of the LXRalpha gene in human macrophages. J. Biol. Chem. 2001, 276:43509-43515.
41. Laffitte B.A., Joseph S.B., Walczak R., Pei L., Wilpitz D.C., Collins J.L., Tontonoz P. Autoregulation of the human liver X receptor alpha promoter. Mol. Cell. Biol. 2001, 21:7558-7568.
42. Chen M., Bradley M.N., Beaven S.W., Tontonoz P. Phosphorylation of the liver X receptors. FEBS Lett. 2006, 580:4835-4841.
43. Torra I.P., Ismaili N., Feig J.E., Xu C.F., Cavasotto C., Pancratov R., Rogatsky I., Neubert T.A., Fisher E.A., Garabedian M.J. Phosphorylation of liver X receptor alpha selectively regulates target gene expression in macrophages. Mol. Cell. Biol. 2008, 28:2626-2636.
44. Anthonisen E.H., Berven L., Holm S., Nygard M., Nebb H.I., Gronning-Wang L.M. Nuclear receptor liver X receptor is O-GlcNAc-modified in response to glucose. J. Biol. Chem. 2010, 285:1607-1615.
45. Peet D.J., Turley S.D., Ma W., Janowski B.A., Lobaccaro J.M., Hammer R.E., Mangelsdorf D.J. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 1998, 93:693-704.
46. Repa J.J., Mangelsdorf D.J. The liver X receptor gene team: potential new players in atherosclerosis. Nat. Med. 2002, 8:1243-1248.
47. Repa J.J., Berge K.E., Pomajzl C., Richardson J.A., Hobbs H., Mangelsdorf D.J. Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J. Biol. Chem. 2002, 277:18793-18800.
48. Castrillo A., Tontonoz P. Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation. Annu. Rev. Cell Dev. Biol. 2004, 20:455-480.
49. Venkateswaran A., Laffitte B.A., Joseph S.B., Mak P.A., Wilpitz D.C., Edwards P.A., Tontonoz P. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc. Natl Acad. Sci. USA 2000, 97:12097-12102.
50. Costet P., Luo Y., Wang N., Tall A.R. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J. Biol. Chem. 2000, 275:28240-28245.
51. Schwartz K., Lawn R.M., Wade D.P. ABC1 gene expression and ApoA-I-mediated cholesterol efflux are regulated by LXR. Biochem. Biophys. Res. Commun. 2000, 274:794-802.
52. Repa J.J., Turley S.D., Lobaccaro J.A., Medina J., Li L., Lustig K., Shan B., Heyman R.A., Dietschy J.M., Mangelsdorf D.J. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 2000, 289:1524-1529.
53. Venkateswaran A., Repa J.J., Lobaccaro J.M., Bronson A., Mangelsdorf D.J., Edwards P.A. Human white/murine ABC8 mRNA levels are highly induced in lipid-loaded macrophages, A transcriptional role for specific oxysterols. J. Biol. Chem. 2000, 275:14700-14707.
54. Laffitte B.A., Repa J.J., Joseph S.B., Wilpitz D.C., Kast H.R., Mangelsdorf D.J., Tontonoz P. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc. Natl Acad. Sci. USA 2001, 98:507-512.
55. Mak P.A., Laffitte B.A., Desrumaux C., Joseph S.B., Curtiss L.K., Mangelsdorf D.J., Tontonoz P., Edwards P.A. Regulated expression of the apolipoprotein E/C-I/C-IV/C-II gene cluster in murine and human macrophages. A critical role for nuclear liver X receptors alpha and beta. J. Biol. Chem. 2002, 277:31900-31908.
56. Repa J.J., Liang G., Ou J., Bashmakov Y., Lobaccaro J.M., Shimomura I., Shan B., Brown M.S., Goldstein J.L., Mangelsdorf D.J. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev. 2000, 14:2819-2830.
57. Joseph S.B., Laffitte B.A., Patel P.H., Watson M.A., Matsukuma K.E., Walczak R., Collins J.L., Osborne T.F., Tontonoz P. Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J. Biol. Chem. 2002, 277:11019-11025.
58. Laffitte B.A., Joseph S.B., Chen M., Castrillo A., Repa J., Wilpitz D., Mangelsdorf D., Tontonoz P. The phospholipid transfer protein gene is a liver X receptor target expressed by macrophages in atherosclerotic lesions. Mol. Cell. Biol. 2003, 23:2182-2191.
59. Molteni V., Li X., Nabakka J., Liang F., Wityak J., Koder A., Vargas L., Romeo R., Mitro N., Mak P.A., Seidel H.M., Haslam J.A., Chow D., Tuntland T., Spalding T.A., Brock A., Bradley M., Castrillo A., Tontonoz P., Saez E. N-Acylthiadiazolines, a new class of liver X receptor agonists with selectivity for LXRbeta. J. Med. Chem. 2007, 50:4255-4259.
60. Gordon S. The macrophage: past, present and future. Eur. J. Immunol. 2007, 37(Suppl 1):S9-S17.
61. Gordon S., Taylor P.R. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 2005, 5:953-964.
62. Geissmann F., Manz M.G., Jung S., Sieweke M.H., Merad M., Ley K. Development of monocytes, macrophages, and dendritic cells. Science 2010, 327:656-661.
63. Shibata N., Glass C.K. Regulation of macrophage function in inflammation and atherosclerosis. J. Lipid Res. 2009, 50(Suppl):S277-S281.
64. Libby P., Ridker P.M., Hansson G.K. Inflammation in atherosclerosis: from pathophysiology to practice. J. Am. Coll. Cardiol. 2009, 54:2129-2138.
65. Ross R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 1999, 340:115-126.
66. Glass C.K., Witztum J.L. Atherosclerosis. the road ahead. Cell 2001, 104:503-516.
67. Aiello R.J., Brees D., Bourassa P.A., Royer L., Lindsey S., Coskran T., Haghpassand M., Francone O.L. Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages. Arterioscler. Thromb. Vasc. Biol. 2002, 22:630-637.
68. van Eck M., Bos I.S., Kaminski W.E., Orso E., Rothe G., Twisk J., Bottcher A., Van Amersfoort E.S., Christiansen-Weber T.A., Fung-Leung W.P., Van Berkel T.J., Schmitz G. Leukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues. Proc. Natl Acad. Sci. USA 2002, 99:6298-6303.
69. Haghpassand M., Bourassa P.A., Francone O.L., Aiello R.J. Monocyte/macrophage expression of ABCA1 has minimal contribution to plasma HDL levels. J. Clin. Invest. 2001, 108:1315-1320.
70. Kennedy M.A., Barrera G.C., Nakamura K., Baldan A., Tarr P., Fishbein M.C., Frank J., Francone O.L., Edwards P.A. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab. 2005, 1:121-131.
71. Baldan A., Pei L., Lee R., Tarr P., Tangirala R.K., Weinstein M.M., Frank J., Li A.C., Tontonoz P., Edwards P.A. Impaired development of atherosclerosis in hyperlipidemic Ldlr-/- and ApoE-/- mice transplanted with Abcg1-/- bone marrow. Arterioscler. Thromb. Vasc. Biol. 2006, 26:2301-2307.
72. Out R., Hoekstra M., Hildebrand R.B., Kruit J.K., Meurs I., Li Z., Kuipers F., Van Berkel T.J., Van Eck M. Macrophage ABCG1 deletion disrupts lipid homeostasis in alveolar macrophages and moderately influences atherosclerotic lesion development in LDL receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2006, 26:2295-2300.
73. Ranalletta M., Wang N., Han S., Yvan-Charvet L., Welch C., Tall A.R. Decreased atherosclerosis in low-density lipoprotein receptor knockout mice transplanted with Abcg1-/- bone marrow. Arterioscler. Thromb. Vasc. Biol. 2006, 26:2308-2315.
74. Yvan-Charvet L., Ranalletta M., Wang N., Han S., Terasaka N., Li R., Welch C., Tall A.R. Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J. Clin. Invest. 2007, 117:3900-3908.
75. Out R., Hoekstra M., Habets K., Meurs I., de Waard V., Hildebrand R.B., Wang Y., Chimini G., Kuiper J., Van Berkel T.J., Van Eck M. Combined deletion of macrophage ABCA1 and ABCG1 leads to massive lipid accumulation in tissue macrophages and distinct atherosclerosis at relatively low plasma cholesterol levels. Arterioscler. Thromb. Vasc. Biol. 2008, 28:258-264.
76. Curtiss L.K. ApoE in atherosclerosis: a protein with multiple hats. Arterioscler. Thromb. Vasc. Biol. 2000, 20:1852-1853.
77. Zhang Y., Repa J.J., Gauthier K., Mangelsdorf D.J. Regulation of lipoprotein lipase by the oxysterol receptors, LXRalpha and LXRbeta. J. Biol. Chem. 2001, 276:43018-43024.
78. Desrumaux C.M., Mak P.A., Boisvert W.A., Masson D., Stupack D., Jauhiainen M., Ehnholm C., Curtiss L.K. Phospholipid transfer protein is present in human atherosclerotic lesions and is expressed by macrophages and foam cells. J. Lipid Res. 2003, 44:1453-1461.
79. Strauss J.G., Frank S., Kratky D., Hammerle G., Hrzenjak A., Knipping G., von Eckardstein A., Kostner G.M., Zechner R. Adenovirus-mediated rescue of lipoprotein lipase-deficient mice. Lipolysis of triglyceride-rich lipoproteins is essential for high density lipoprotein maturation in mice. J. Biol. Chem. 2001, 276:36083-36090.
80. Zelcer N., Hong C., Boyadjian R., Tontonoz P. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science 2009, 325:100-104.
81. Hong C., Duit S., Jalonen P., Out R., Scheer L., Sorrentino V., Boyadjian R., Rodenburg K.W., Foley E., Korhonen L., Lindholm D., Nimpf J., van Berkel T.J., Tontonoz P., Zelcer N. The E3 ubiquitin ligase IDOL induces the degradation of the low density lipoprotein receptor family members VLDLR and ApoER2. J. Biol. Chem. 2010, 285:19720-19726.
82. Tangirala R.K., Bischoff E.D., Joseph S.B., Wagner B.L., Walczak R., Laffitte B.A., Daige C.L., Thomas D., Heyman R.A., Mangelsdorf D.J., Wang X., Lusis A.J., Tontonoz P., Schulman I.G. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc. Natl Acad. Sci. USA 2002, 99:11896-11901.
83. Schuster G.U., Parini P., Wang L., Alberti S., Steffensen K.R., Hansson G.K., Angelin B., Gustafsson J.A. Accumulation of foam cells in liver X receptor-deficient mice. Circulation 2002, 106:1147-1153.
84. Calkin A.C., Tontonoz P. Liver x receptor signaling pathways and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2010, 30:1513-1518.
85. Joseph S.B., McKilligin E., Pei L., Watson M.A., Collins A.R., Laffitte B.A., Chen M., Noh G., Goodman J., Hagger G.N., Tran J., Tippin T.K., Wang X., Lusis A.J., Hsueh W.A., Law R.E., Collins J.L., Willson T.M., Tontonoz P. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl Acad. Sci. USA 2002, 99:7604-7609.
86. Terasaka N., Hiroshima A., Koieyama T., Ubukata N., Morikawa Y., Nakai D., Inaba T. T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett. 2003, 536:6-11.
87. Lehrke M., Lebherz C., Millington S.C., Guan H.P., Millar J., Rader D.J., Wilson J.M., Lazar M.A. Diet-dependent cardiovascular lipid metabolism controlled by hepatic LXRalpha. Cell Metab. 2005, 1:297-308.
88. Teupser D., Kretzschmar D., Tennert C., Burkhardt R., Wilfert W., Fengler D., Naumann R., Sippel A.E., Thiery J. Effect of macrophage overexpression of murine liver X receptor-alpha (LXR-alpha) on atherosclerosis in LDL-receptor deficient mice. Arterioscler. Thromb. Vasc. Biol. 2008, 28:2009-2015.
89. Bischoff E.D., Daige C.L., Petrowski M., Dedman H., Pattison J., Juliano J., Li A.C., Schulman I.G. Non-redundant roles for LXRalpha and LXRbeta in atherosclerosis susceptibility in low density lipoprotein receptor knockout mice. J. Lipid Res. 2010, 51:900-906.
90. Bradley M.N., Hong C., Chen M., Joseph S.B., Wilpitz D.C., Wang X., Lusis A.J., Collins A., Hseuh W.A., Collins J.L., Tangirala R.K., Tontonoz P. Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE. J. Clin. Invest. 2007, 117:2337-2346.
91. Lo Sasso G., Murzilli S., Salvatore L., D'Errico I., Petruzzelli M., Conca P., Jiang Z.Y., Calabresi L., Parini P., Moschetta A. Intestinal specific LXR activation stimulates reverse cholesterol transport and protects from atherosclerosis. Cell Metab. 2010, 12:187-193.
92. Tabas I. The role of endoplasmic reticulum stress in the progression of atherosclerosis. Circ. Res. 2010, 107:839-850.
93. Erbay E., Babaev V.R., Mayers J.R., Makowski L., Charles K.N., Snitow M.E., Fazio S., Wiest M.M., Watkins S.M., Linton M.F., Hotamisligil G.S. Reducing endoplasmic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosis. Nat. Med. 2009, 15:1383-1391.
94. Makowski L., Brittingham K.C., Reynolds J.M., Suttles J., Hotamisligil G.S. The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and IkappaB kinase activities. J. Biol. Chem. 2005, 280:12888-12895.
95. Furuhashi M., Tuncman G., Gorgun C.Z., Makowski L., Atsumi G., Vaillancourt E., Kono K., Babaev V.R., Fazio S., Linton M.F., Sulsky R., Robl J.A., Parker R.A., Hotamisligil G.S. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 2007, 447:959-965.
96. Hotamisligil G.S., Erbay E. Nutrient sensing and inflammation in metabolic diseases. Nat. Rev. Immunol. 2008, 8:923-934.
97. S. Gordon, F.O. Martin ez, Alternative activation of macrophages: mechanism and functions, Immunity 32, 593-604.
98. Medzhitov R., Horng T. Transcriptional control of the inflammatory response. Nat. Rev. Immunol. 2009, 9:692-703.
99. Glass C.K., Saijo K., Winner B., Marchetto M.C., Gage F.H. Mechanisms underlying inflammation in neurodegeneration. Cell 2010, 140:918-934.
100. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
101. Whitsett J.A., Wert S.E., Weaver T.E. Alveolar surfactant homeostasis and the pathogenesis of pulmonary disease. Annu. Rev. Med. 2010, 61:105-119.
102. Fadok V., Bratton D., Konowal A., Freed P., Westcott J., Henson P. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J. Clin. Invest. 1998, 101:890-898.
103. Voll R.E., Herrmann M., Roth E.A., Stach C., Kalden J.R., Girkontaite I. Immunosuppressive effects apoptotic cells. Nature 1997, 390:350-351.
104. Sakai D.D., Helms S., Carlstedt-Duke J., Gustafsson J.A., Rottman F.M., Yamamoto K.R. Hormone-mediated repression: a negative glucocorticoid response element from the bovine prolactin gene. Genes Dev. 1988, 2:1144-1154.
105. Chawla A. Control of macrophage activation and function by PPARs. Circ. Res. 2010, 106:1559-1569.
106. Yang-Yen H.F., Chambard J.C., Sun Y.L., Smeal T., Schmidt T.J., Drouin J., Karin M. Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. Cell 1990, 62:1205-1215.
107. Schule R., Rangarajan P., Kliewer S., Ransone L.J., Bolado J., Yang N., Verma I.M., Evans R.M. Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor. Cell 1990, 62:1217-1226.
108. Newton R., Holden N.S. Separating transrepression and transactivation: a distressing divorce for the glucocorticoid receptor?. Mol. Pharmacol. 2007, 72:799-809.
109. Pascual G., Fong A.L., Ogawa S., Gamliel A., Li A.C., Perissi V., Rose D.W., Willson T.M., Rosenfeld M.G., Glass C.K. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005, 437:759-763.
110. Joseph S.B., Castrillo A., Laffitte B.A., Mangelsdorf D.J., Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat. Med. 2003, 9:213-219.
111. Castrillo A., Joseph S.B., Marathe C., Mangelsdorf D.J., Tontonoz P. Liver X receptor-dependent repression of matrix metalloproteinase-9 expression in macrophages. J. Biol. Chem. 2003, 278:10443-10449.
112. Fowler A.J., Sheu M.Y., Schmuth M., Kao J., Fluhr J.W., Rhein L., Collins J.L., Willson T.M., Mangelsdorf D.J., Elias P.M., Feingold K.R. Liver X receptor activators display anti-inflammatory activity in irritant and allergic contact dermatitis models: liver-X-receptor-specific inhibition of inflammation and primary cytokine production. J. Invest. Dermatol. 2003, 120:246-255.
113. Ghisletti S., Huang W., Ogawa S., Pascual G. L. M., T.M. Willson, M.G. Rosenfeld, C.K. Glass, Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgamma. Mol. Cell 2007, 25:57-70.
114. Blaschke F., Takata Y., Caglayan E., Collins A., Tontonoz P., Hsueh W.A., Tangirala R.K. A nuclear receptor corepressor-dependent pathway mediates suppression of cytokine-induced C-reactive protein gene expression by liver X receptor. Circ. Res. 2006, 99:e88-e99.
115. Lee J.H., Park S.M., Kim O.S., Lee C.S., Woo J.H., Park S.J., Joe E.H., Jou I. Differential SUMOylation of LXRalpha and LXRbeta mediates transrepression of STAT1 inflammatory signaling in IFN-gamma-stimulated brain astrocytes. Mol. Cell 2009, 35:806-817.
116. Venteclef N., Jakobsson T., Ehrlund A., Damdimopoulos A., Mikkonen L., Ellis E., Nilsson L.M., Parini P., Janne O.A., Gustafsson J.A., Steffensen K.R., Treuter E. GPS2-dependent corepressor/SUMO pathways govern anti-inflammatory actions of LRH-1 and LXRbeta in the hepatic acute phase response. Genes Dev. 2010, 24:381-395.
117. Ogawa S., Lozach J., Benner C., Pascual G., Tangirala R.K., Westin S., Hoffmann A., Subramaniam S., David M., Rosenfeld M.G., Glass C.K. Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 2005, 122:707-721.
118. Scheinman R.I., Cogswell P.C., Lofquist A.K., Baldwin A.S. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 1995, 270:283-286.
119. Auphan N., DiDonato J.A., Rosette C., Helmberg A., Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995, 270:286-290.
120. Huang J.T., Welch J.S., Ricote M., Binder C.J., Willson T.M., Kelly C., Witztum J.L., Funk C.D., Conrad D., Glass C.K. Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature 1999, 400:378-382.
121. Bouhlel M.A., Derudas B., Rigamonti E., Dievart R., Brozek J., Haulon S., Zawadzki C., Jude B., Torpier G., Marx N., Staels B., Chinetti-Gbaguidi G. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 2007, 6:137-143.
122. Odegaard J.I., Ricardo-Gonzalez R.R., Goforth M.H., Morel C.R., Subramanian V., Mukundan L., Red Eagle A., Vats D., Brombacher F., Ferrante A.W., Chawla A. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 2007, 447:1116-1120.
123. Odegaard J.I., Ricardo-Gonzalez R.R., Red Eagle A., Vats D., Morel C.R., Goforth M.H., Subramanian V., Mukundan L., Ferrante A.W., Chawla A. Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. Cell Metab. 2008, 7:496-507.
124. Hevener A.L., Olefsky J.M., Reichart D., Nguyen M.T., Bandyopadyhay G., Leung H.Y., Watt M.J., Benner C., Febbraio M.A., Nguyen A.K., Folian B., Subramaniam S., Gonzalez F.J., Glass C.K., Ricote M. Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J. Clin. Invest. 2007, 117:1658-1669.
125. Guri A.J., Hontecillas R., Ferrer G., Casagran O., Wankhade U., Noble A.M., Eizirik D.L., Ortis F., Cnop M., Liu D., Si H., Bassaganya-Riera J. Loss of PPAR gamma in immune cells impairs the ability of abscisic acid to improve insulin sensitivity by suppressing monocyte chemoattractant protein-1 expression and macrophage infiltration into white adipose tissue. J. Nutr. Biochem. 2008, 19:216-228.
126. Kang K., Reilly S.M., Karabacak V., Gangl M.R., Fitzgerald K., Hatano B., Lee C.H. Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. Cell Metab. 2008, 7:485-495.
127. Gallardo-Soler A., Gomez-Nieto C., Campo M.L., Marathe C., Tontonoz P., Castrillo A., Corraliza I. Arginase I induction by modified lipoproteins in macrophages: a peroxisome proliferator-activated receptor-gamma/delta-mediated effect that links lipid metabolism and immunity. Mol. Endocrinol. 2008, 22:1394-1402.
128. Szanto A., Balint B.L., Nagy Z.S., Barta E., Dezso B., Pap A., Szeles L., Poliska S., Oros M., Evans R.M., Barak Y., Schwabe J., Nagy L. STAT6 transcription factor is a facilitator of the nuclear receptor PPARgamma-regulated gene expression in macrophages and dendritic cells. Immunity 2010, 33:699-712.
129. Marathe C., Bradley M.N., Hong C., Chao L., Wilpitz D., Salazar J., Tontonoz P. Preserved glucose tolerance in high-fat-fed C57BL/6 mice transplanted with PPARgamma-/-, PPARdelta-/-, PPARgammadelta-/-, or LXRalphabeta-/- bone marrow. J. Lipid. Res. 2009, 50:214-224.
130. Laffitte B.A., Chao L.C., Li J., Walczak R., Hummasti S., Joseph S.B., Castrillo A., Wilpitz D.C., Mangelsdorf D.J., Collins J.L., Saez E., Tontonoz P. Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc. Natl Acad. Sci. USA 2003, 100:5419-5424.
131. Commerford S.R., Vargas L., Dorfman S.E., Mitro N., Rocheford E.C., Mak P.A., Li X., Kennedy P., Mullarkey T.L., Saez E. Dissection of the insulin-sensitizing effect of liver X receptor ligands. Mol. Endocrinol. 2007, 21:3002-3012.
132. Marathe C., Bradley M.N., Hong C., Lopez F., Ruiz de Galarreta C.M., Tontonoz P., Castrillo A. The arginase II gene is an anti-inflammatory target of liver X receptor in macrophages. J. Biol. Chem. 2006, 281:32197-32206.
133. Iniesta V., Gomez-Nieto L.C., Corraliza I. The inhibition of arginase by N(omega)-hydroxy-l-arginine controls the growth of Leishmania inside macrophages. J. Exp. Med. 2001, 193:777-784.
134. El Kasmi K.C., Qualls J.E., Pesce J.T., Smith A.M., Thompson R.W., Henao-Tamayo M., Basaraba R.J., Konig T., Schleicher U., Koo M.S., Kaplan G., Fitzgerald K.A., Tuomanen E.I., Orme I.M., Kanneganti T.D., Bogdan C., Wynn T.A., Murray P.J. Toll-like receptor-induced arginase 1 in macrophages thwarts effective immunity against intracellular pathogens. Nat. Immunol. 2008, 9:1399-1406.
135. Ghisletti S., Huang W., Jepsen K., Benner C., Hardiman G., Rosenfeld M.G., Glass C.K. Cooperative NCoR/SMRT interactions establish a corepressor-based strategy for integration of inflammatory and anti-inflammatory signaling pathways. Genes Dev. 2009, 23:681-693.
136. Terasaka N., Hiroshima A., Ariga A., Honzumi S., Koieyama T., Inaba T., Fujiwara T. Liver X receptor agonists inhibit tissue factor expression in macrophages. FEBS J. 2005, 272:1546-1556.
137. Andersson S., Gustafsson N., Warner M., Gustafsson J.A. Inactivation of liver X receptor beta leads to adult-onset motor neuron degeneration in male mice. Proc. Natl Acad. Sci. USA 2005, 102:3857-3862.
138. Fan X., Kim H.J., Bouton D., Warner M., Gustafsson J.A. Expression of liver X receptor beta is essential for formation of superficial cortical layers and migration of later-born neurons. Proc. Natl Acad. Sci. USA 2008, 105:13445-13450.
139. Kim H.J., Fan X., Gabbi C., Yakimchuk K., Parini P., Warner M., Gustafsson J.A. Liver X receptor beta (LXRbeta): a link between beta-sitosterol and amyotrophic lateral sclerosis-Parkinson's dementia. Proc. Natl Acad. Sci. USA 2008, 105:2094-2099.
140. Jiang Q., Lee C.Y., Mandrekar S., Wilkinson B., Cramer P., Zelcer N., Mann K., Lamb B., Willson T.M., Collins J.L., Richardson J.C., Smith J.D., Comery T.A., Riddell D., Holtzman D.M., Tontonoz P., Landreth G.E. ApoE promotes the proteolytic degradation of Abeta. Neuron 2008, 58:681-693.
141. Zelcer N., Khanlou N., Clare R., Jiang Q., Reed-Geaghan E.G., Landreth G.E., Vinters H.V., Tontonoz P. Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. Proc. Natl Acad. Sci. USA 2007, 104:10601-10606.
142. Hindinger C., Hinton D.R., Kirwin S.J., Atkinson R.D., Burnett M.E., Bergmann C.C., Stohlman S.A. Liver X receptor activation decreases the severity of experimental autoimmune encephalomyelitis. J. Neurosci. Res. 2006, 84:1225-1234.
143. Fitz N.F., Cronican A., Pham T., Fogg A., Fauq A.H., Chapman R., Lefterov I., Koldamova R. Liver X receptor agonist treatment ameliorates amyloid pathology and memory deficits caused by high-fat diet in APP23 mice. J. Neurosci. 2010, 30:6862-6872.
144. Morales J.R., Ballesteros I., Deniz J.M., Hurtado O., Vivancos J., Nombela F., Lizasoain I., Castrillo A., Moro M.A. Activation of liver X receptors promotes neuroprotection and reduces brain inflammation in experimental stroke. Circulation 2008, 118:1450-1459.
145. Sironi L., Mitro N., Cimino M., Gelosa P., Guerrini U., Tremoli E., Saez E. Treatment with LXR agonists after focal cerebral ischemia prevents brain damage. FEBS Lett. 2008, 582:3396-3400.
146. Cheng O., Ostrowski R.P., Liu W., Zhang J.H. Activation of liver X receptor reduces global ischemic brain injury by reduction of nuclear factor-kappaB. Neuroscience 2010, 166:1101-1109.
147. Gupta D.S., Kaul D., Kanwar A.J., Parsad D. Psoriasis: crucial role of LXR-alpha RNomics. Genes Immun. 2010, 11:37-44.
148. Chang K.C., Shen Q., Oh I.G., Jelinsky S.A., Jenkins S.F., Wang W., Wang Y., LaCava M., Yudt M.R., Thompson C.C., Freedman L.P., Chung J.H., Nagpal S. Liver X receptor is a therapeutic target for photoaging and chronological skin aging. Mol. Endocrinol. 2008, 22:2407-2419.
149. Gong H., He J., Lee J.H., Mallick E., Gao X., Li S., Homanics G.E., Xie W. Activation of the liver X receptor prevents lipopolysaccharide-induced lung injury. J. Biol. Chem. 2009, 284:30113-30121.
150. Smoak K., Madenspacher J., Jeyaseelan S., Williams B., Dixon D., Poch K.R., Nick J.A., Worthen G.S., Fessler M.B. Effects of liver X receptor agonist treatment on pulmonary inflammation and host defense. J. Immunol. 2008, 180:3305-3312.
151. Bauler L.D., Duckett C.S., O'Riordan M.X. XIAP regulates cytosol-specific innate immunity to Listeria infection. PLoS Pathog. 2008, 4:e1000142.
152. O'Connell R.M., Saha S.K., Vaidya S.A., Bruhn K.W., Miranda G.A., Zarnegar B., Perry A.K., Nguyen B.O., Lane T.F., Taniguchi T., Miller J.F., Cheng G. Type I interferon production enhances susceptibility to Listeria monocytogenes infection. J. Exp. Med. 2004, 200:437-445.
153. Miyazaki T., Hirokami Y., Matsuhashi N., Takatsuka H., Naito M. Increased susceptibility of thymocytes to apoptosis in mice lacking AIM, a novel murine macrophage-derived soluble factor belonging to the scavenger receptor cysteine-rich domain superfamily. J. Exp. Med. 1999, 189:413-422.
154. Valledor A.F., Hsu L.C., Ogawa S., Sawka-Verhelle D., Karin M., Glass C.K. Activation of liver X receptors and retinoid X receptors prevents bacterial-induced macrophage apoptosis. Proc. Natl Acad. Sci. USA 2004, 101:17813-17818.
155. Arai S., Shelton J.M., Chen M., Bradley M.N., Castrillo A., Bookout A.L., Mak P.A., Edwards P.A., Mangelsdorf D.J., Tontonoz P., Miyazaki T. A role for the apoptosis inhibitory factor AIM/Spalpha/Api6 in atherosclerosis development. Cell Metab. 2005, 1:201-213.
156. Korf H., Vander Beken S., Romano M., Steffensen K.R., Stijlemans B., Gustafsson J.A., Grooten J., Huygen K. Liver X receptors contribute to the protective immune response against Mycobacterium tuberculosis in mice. J. Clin. Invest. 2009, 119:1626-1637.
157. Castrillo A., Joseph S.B., Vaidya S.A., Haberland M., Fogelman A.M., Cheng G., Tontonoz P. Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol. Cell 2003, 12:805-816.
158. Cao F., Castrillo A., Tontonoz P., Re F., Byrne G.I. Chlamydia pneumoniae-induced macrophage foam cell formation is mediated by Toll-like receptor 2. Infect. Immun. 2007, 75:753-759.
159. Naiki Y., Sorrentino R., Wong M.H., Michelsen K.S., Shimada K., Chen S., Yilmaz A., Slepenkin A., Schroder N.W., Crother T.R., Bulut Y., Doherty T.M., Bradley M., Shaposhnik Z., Peterson E.M., Tontonoz P., Shah P.K., Arditi M. TLR/MyD88 and liver X receptor alpha signaling pathways reciprocally control Chlamydia pneumoniae-induced acceleration of atherosclerosis. J. Immunol. 2008, 181:7176-7185.
160. Chen S., Sorrentino R., Shimada K., Bulut Y., Doherty T.M., Crother T.R., Arditi M. Chlamydia pneumoniae-induced foam cell formation requires MyD88-dependent and -independent signaling and is reciprocally modulated by liver X receptor activation. J. Immunol. 2008, 181:7186-7193.
161. Geyeregger R., Zeyda M., Bauer W., Kriehuber E., Saemann M.D., Zlabinger G.J., Maurer D., Stulnig T.M. Liver X receptors regulate dendritic cell phenotype and function through blocked induction of the actin-bundling protein fascin. Blood 2007, 109:4288-4295.
162. Villablanca E.J., Raccosta L., Zhou D., Fontana R., Maggioni D., Negro A., Sanvito F., Ponzoni M., Valentinis B., Bregni M., Prinetti A., Steffensen K.R., Sonnino S., Gustafsson J.A., Doglioni C., Bordignon C., Traversari C., Russo V. Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses. Nat. Med. 2010, 16:98-105.
163. Torocsik D., Barath M., Benko S., Szeles L., Dezso B., Poliska S., Hegyi Z., Homolya L., Szatmari I., Lanyi A., Nagy L. Activation of liver X receptor sensitizes human dendritic cells to inflammatory stimuli. J. Immunol. 2010, 184:5456-5465.
164. Bensinger S.J., Bradley M.N., Joseph S.B., Zelcer N., Janssen E.M., Hausner M.A., Shih R., Parks J.S., Edwards P.A., Jamieson B.D., Tontonoz P. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell 2008, 134:97-111.
165. Feig J.E., Pineda-Torra I., Sanson M., Bradley M.N., Vengrenyuk Y., Bogunovic D., Gautier E.L., Rubinstein D., Hong C., Liu J., Wu C., van Rooijen N., Bhardwaj N., Garabedian M.J., Tontonoz P., Fisher E.A. LXR promotes the maximal egress of monocyte-derived cells from mouse aortic plaques during atherosclerosis regression. J. Clin. Invest. 2010.
166. Ravichandran K.S., Lorenz U. Engulfment of apoptotic cells: signals for a good meal. Nat. Rev. Immunol. 2007, 7:964-974.
167. Vandivier R.W., Henson P.M., Douglas I.S. Burying the dead: the impact of failed apoptotic cell removal (efferocytosis) on chronic inflammatory lung disease. Chest 2006, 129:1673-1682.
168. Lauber K., Blumenthal S., Waibel M., Wesselborg S. Clearance of apoptotic cells: getting rid of the corpses. Mol. Cell 2004, 14:277-287.
169. Elliott M.R., Chekeni F.B., Trampont P.C., Lazarowski E.R., Kadl A., Walk S.F., Park D., Woodson R.I., Ostankovich M., Sharma P., Lysiak J.J., Harden T.K., Leitinger N., Ravichandran K.S. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 2009, 461:282-286.
170. Lauber K., Bohn E., Krober S.M., Xiao Y.J., Blumenthal S.G., Lindemann R.K., Marini P., Wiedig C., Zobywalski A., Baksh S., Xu Y., Autenrieth I.B., Schulze-Osthoff K., Belka C., Stuhler G., Wesselborg S. Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell 2003, 113:717-730.
171. Ravichandran K.S. Find-me and eat-me signals in apoptotic cell clearance: progress and conundrums. J. Exp. Med. 2010, 207:1807-1817.
172. Munoz L.E., Lauber K., Schiller M., Manfredi A.A., Herrmann M. The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat. Rev. Rheumatol. 2010, 6:280-289.
173. A.G.N, Bensinger S.J., Hong C., Beceiro S., Bradley M.N., Zelcer N., Deniz J., Ramirez C., Diaz M., Gallardo G., de Galarreta C.R., Salazar J., Lopez F., Edwards P., Parks J., Andujar M., Tontonoz P., Castrillo A. Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity 2009, 31:245-258.
174. Lemke G., Burstyn-Cohen T. TAM receptors and the clearance of apoptotic cells. Ann. N. Y. Acad. Sci. 2010, 1209:23-29.
175. Rebe C., Raveneau M., Chevriaux A., Lakomy D., Sberna A.L., Costa A., Bessede G., Athias A., Steinmetz E., Lobaccaro J.M., Alves G., Menicacci A., Vachenc S., Solary E., Gambert P., Masson D. Induction of transglutaminase 2 by a liver X receptor/retinoic acid receptor alpha pathway increases the clearance of apoptotic cells by human macrophages. Circ. Res. 2009, 105:393-401.
176. Nagy L., Saydak M., Shipley N., Lu S., Basilion J.P., Yan Z.H., Syka P., Chandraratna R.A., Stein J.P., Heyman R.A., Davies P.J. Identification and characterization of a versatile retinoid response element (retinoic acid receptor response element-retinoid X receptor response element) in the mouse tissue transglutaminase gene promoter. J. Biol. Chem. 1996, 271:4355-4365.
177. Melino G., Draoui M., Bellincampi L., Bernassola F., Bernardini S., Piacentini M., Reichert U., Cohen P. Retinoic acid receptors alpha and gamma mediate the induction of "tissue" transglutaminase activity and apoptosis in human neuroblastoma cells. Exp. Cell Res. 1997, 235:55-61.
178. Szondy Z., Sarang Z., Molnar P., Nemeth T., Piacentini M., Mastroberardino P.G., Falasca L., Aeschlimann D., Kovacs J., Kiss I., Szegezdi E., Lakos G., Rajnavolgyi E., Birckbichler P.J., Melino G., Fesus L. Transglutaminase 2-/- mice reveal a phagocytosis-associated crosstalk between macrophages and apoptotic cells. Proc. Natl Acad. Sci. USA 2003, 100:7812-7817.
179. Hamon Y., Broccardo C., Chambenoit O., Luciani M., Toti F., Chaslin S., Freyssinet J., Devaux P., McNeish J., Marguet D., Chimini G. ABC1 promotes engulfment of apoptotic cells and transbilayer redistribution of phosphatidylserine. Nat. Cell Biol. 2000, 2:399-406.
180. Li Y., Gerbod-Giannone M.C., Seitz H., Cui D., Thorp E., Tall A.R., Matsushima G.K., Tabas I. Cholesterol-induced apoptotic macrophages elicit an inflammatory response in phagocytes, which is partially attenuated by the Mer receptor. J. Biol. Chem. 2006, 281:6707-6717.
181. Kiss R., Elliott M., Ma Z., Marcel Y., Ravichandran K. Apoptotic cells induce a phosphatidylserine-dependent homeostatic response from phagocytes. Curr. Biol. 2006, 16:2252-2258.
182. Gerbod-Giannone M.C., Li Y., Holleboom A., Han S., Hsu L.C., Tabas I., Tall A.R. TNFalpha induces ABCA1 through NF-kappaB in macrophages and in phagocytes ingesting apoptotic cells. Proc. Natl Acad. Sci. USA 2006, 103:3112-3117.
183. Rodriguez-Manzanet R., Sanjuan M.A., Wu H.Y., Quintana F.J., Xiao S., Anderson A.C., Weiner H.L., Green D.R., Kuchroo V.K. T and B cell hyperactivity and autoimmunity associatedwith niche-specific defects in apoptotic body clearance in TIM-4-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:8706-8711.
184. Lacy-Hulbert A., Smith A.M., Tissire H., Barry M., Crowley D., Bronson R.T., Roes J.T., Savill J.S., Hynes R.O. Ulcerative colitis and autoimmunity induced by loss of myeloid alphav integrins. Proc. Natl Acad. Sci. USA 2007, 104:15823-15828.
185. Botto M., Dell'Agnola C., Bygrave A., Thompson E., Cook H.T., Petry F., Loos M., Pandolfi P.P., Walport M.J. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat. Genet. 1998, 19:56-59.
186. Hanayama R., Tanaka M., Miyasaka K., Aozasa K., Koike M., Uchiyama Y., Nagata S. Autoimmune disease and impaired uptake of apoptotic cells in MFG-E8-deficient mice. Science 2004, 304:1147-1150.
187. Cohen P.L., Caricchio R., Abraham V., Camenisch T., Jennette J.C., Roubey R.A., Earp H.S., Matsushima G., Reap E. Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. J. Exp. Med. 2002, 196:135-140.
188. Mukundan L., Odegaard J.I., Morel C.R., Heredia J.E., Mwangi J.W., Ricardo-Gonzalez R.R., Goh Y.P., Eagle A.R., Dunn S.E., Awakuni J.U., Nguyen K.D., Steinman L., Michie S.A., Chawla A. PPAR-delta senses and orchestrates clearance of apoptotic cells to promote tolerance. Nat. Med. 2009, 15:1266-1272.
189. Yamaguchi H., Fujimoto T., Nakamura S., Ohmura K., Mimori T., Matsuda F., Nagata S. Aberrant splicing of the milk fat globule-EGF factor 8 (MFG-E8) gene in human systemic lupus erythematosus. Eur. J. Immunol. 2010, 40:1778-1785.
190. Fernandez-Boyanapalli R., Frasch S.C., Riches D.W., Vandivier R.W., Henson P.M., Bratton D.L. PPAR{gamma} activation normalizes resolution of acute sterile inflammation in murine chronic granulomatous disease. Blood 2010.
191. Majai G., Gogolak P., Ambrus C., Vereb G., Hodrea J., Fesus L., Rajnavolgyi E. PPAR {gamma} modulated inflammatory response of human dendritic cell subsets to engulfed apoptotic neutrophils. J. Leukoc. Biol. 2010.
192. Majai G., Sarang Z., Csomos K., Zahuczky G., Fesus L. PPARgamma-dependent regulation of human macrophages in phagocytosis of apoptotic cells. Eur. J. Immunol. 2007, 37:1343-1354.
193. Johann A.M., von Knethen A., Lindemann D., Brune B. Recognition of apoptotic cells by macrophages activates the peroxisome proliferator-activated receptor-gamma and attenuates the oxidative burst. Cell Death Differ. 2006, 13:1533-1540.
194. Giles K.M., Ross K., Rossi A.G., Hotchin N.A., Haslett C., Dransfield I. Glucocorticoid augmentation of macrophage capacity for phagocytosis of apoptotic cells is associated with reduced p130Cas expression, loss of paxillin/pyk2 phosphorylation, and high levels of active Rac. J. Immunol. 2001, 167:976-986.
195. Liu Y., Cousin J.M., Hughes J., Van Damme J., Seckl J.R., Haslett C., Dransfield I., Savill J., Rossi A.G. Glucocorticoids promote nonphlogistic phagocytosis of apoptotic leukocytes. J. Immunol. 1999, 162:3639-3646.
196. McColl A., Bournazos S., Franz S., Perretti M., Morgan B.P., Haslett C., Dransfield I. Glucocorticoids induce protein S-dependent phagocytosis of apoptotic neutrophils by human macrophages. J. Immunol. 2009, 183:2167-2175.
197. Ehrchen J., Steinmuller L., Barczyk K., Tenbrock K., Nacken W., Eisenacher M., Nordhues U., Sorg C., Sunderkotter C., Roth J. Glucocorticoids induce differentiation of a specifically activated, anti-inflammatory subtype of human monocytes. Blood 2007, 109:1265-1274.
198. Choi J.H., Banks A.S., Estall J.L., Kajimura S., Bostrom P., Laznik D., Ruas J.L., Chalmers M.J., Kamenecka T.M., Bluher M., Griffin P.R., Spiegelman B.M. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 2010, 466:451-456.
199. Foster S.L., Hargreaves D.C., Medzhitov R. Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 2007, 447:972-978.